Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
